Search Results
Your search for ,kEY matches 7151 pages
Showing 5401 - 5450‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC
OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...
‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC
OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...
Nivolumab Plus Ipilimumab vs Sunitinib Alone as First-Line Therapy for Metastatic Renal Cell Carcinoma
A CHANGE IN PARADIGM may be on the horizon for the treatment of metastatic renal cell carcinoma. According to the results of CheckMate 214, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) outperformed the standard of care—sunitinib (Sutent)—for first-line treatment, with improved...
Molecular Profiling of Key Survival Proteins in B-Cell Lymphoma Subtypes
Investigators at the Sidney Kimmel Cancer Center at Jefferson uncovered potential new proteins that contribute to the development and progression of several types of lymphoma. Their findings were published by Adams et al in Clinical Cancer Research. The researchers focused their attention on...
Association Between Vasectomy and Prostate Cancer
A systematic review and meta-analysis has found no association between vasectomy and high-grade, advanced, or fatal prostate cancer but a weak association with any prostate cancer. These findings were reported in JAMA Oncology by Bimal Bhindi et al. R. Jeffrey Karnes, MD, of the Mayo Clinic,...
Obtaining a Second Graduate Degree During Fellowship: Things to Consider
KAH POH (MELISSA) LOH, MBBCh BAO Institution: Fellow, University of Rochester Medical CenterMember since: 2013ASCO activities: Trainee Council Hematology and oncology fellowship training requires at least 3 years to complete. For fellows who wish to single board in either hematology or oncology, a ...
ASCO’s QOPI Certification Program™ Recognizes Three Oncology Practices in Spain
ASCO has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program™, LLC (QCP). The accreditations were given on September 8, at the European Society for Medical Oncology (ESMO) 2017 Congress in...
ASTRO 2017: Immune Response May Be Prognostic for Prostate Cancer Survival, Recurrence, and Response to Radiation Therapy
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes. The analysis of more than 9,000 prostate tumors also found evidence that programmed cell death...
Rhodiola
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present information on...
How a Child With Cancer Moved From Vulnerability to Resilience
At the time this article was published in the Journal of Clinical Oncology, Dr. Danaher was practicing at Monash -University, -Melbourne, Australia; Drs. Brand and Mack, at Dana-Farber Cancer Institute, Boston; Dr. Pickard, at the Imperial College -Healthcare NHS Trust, London; and Dr. Berry,...
Are You Ready for October 2? Plan Ahead for Key QPP Deadline
AS PRACTICES across the country implement the Quality Payment Program (QPP), it’s important to remember that 2017 is a transition year. Practices only have to report one measure for one patient (including at least one Medicare patient) in order to receive a neutral payment adjustment and avoid...
Original Report in JCO CCI Describes How Authors Developed a Process to Automate a QOPI Measure
A NEW ARTICLE published in JCO Clinical Cancer Informatics (JCO CCI), “Automating QOPI Quality Measure NHL78a,” by Richard P. Mansour, MD, and Samip Master, MD, reports how the authors were able to use data from an electronic health record (EHR) and Microsoft SQL Server database management system...
How Early Palliative Care May Benefit Patients With Incurable Cancer
Palliative care provided soon after a patient is diagnosed with incurable cancer not only helps improve the patient’s overall quality of life but also improves communication about the patient’s wishes for end-of-life care, according to a study by Jennifer S. Temel, MD, Clinical Director of Thoracic ...
Is Complete Lymphadenectomy Still Standard of Care in Melanoma?
DOES COMPLETE lymph node dissection for sentinel node–positive melanoma still have a role in the management of this disease? That’s debatable. Although it does not improve overall survival over observation alone, complete lymphadenectomy may have other benefits, according to a dialogue at the...
PD-L1 Inhibitor Consolidation Therapy for NSCLC: New Standard of Care?
THE PROGRAMMED CELL DEATH ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) improved progression-free survival by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) whose disease did not progress following standard treatment ...
New ASCO Guideline Aims to Improve Clinician Communication With Patients
A new guideline from ASCO published by Gilligan et al in the Journal of Clinical Oncology outlines best practices for cancer clinicians when communicating with patients and their loved ones. The Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline...
ESMO 2017: Patients Struggle With Key Aspects of Clinical Trial Methodology
Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at 3%–5%. A nationwide study in Ireland, the preliminary results of which were presented at the European Society for Medical Oncology...
Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers
Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.
Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian...
ASTRO Welcomes New Officers to Board of Directors
THE MEMBERS of the American Society for Radiation Oncology (ASTRO) have elected three new officers to ASTRO’s Board of Directors and three members to serve on the medical society’s Nominating Committee. The newly elected President-Elect, Health Policy Council Vice-Chair, Science Council Vice-Chair, ...
NCCN Foundation Announces Fifth 2017 Young Investigator Award
THE NCCN Foundation has granted its fifth Young Investigator Award for the 2017 cycle to Liqin Zhu, PhD, of St. Jude Children’s Research Hospital/ University of Tennessee Health Science Center, for the study titled, “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery.”...
Tales From the OR: A Pediatric Surgeon’s Memoir
CARING FOR sick children brings with it a set of emotional and physical challeneges that differ from those with the adult patient population. In a new book, Healing Children: A Surgeon’s Stories From the Frontiers of Pediatric Medicine, Kurt Newman, MD, draws on more than 30 years of his...
FDA Announces New Comprehensive Plan for Tobacco and Nicotine Regulation
Recently, the U.S. Food and Drug Administration (FDA) announced a new strategy to address tobacco-related disease and death. The agency seeks to develop a plan to reduce the nicotine levels in combustible cigarettes to nonaddictive levels. However, as part of the strategy, the FDA also announced it ...
Cancer.Net Resource Helps Patients Manage Cancer Costs
Help your patients manage the financial impact of a cancer diagnosis with Cancer.Net’s Managing the Cost of Cancer Care booklet. This booklet provides information on key financial categories for cancer care, an easy-to-understand explanation of health insurance coverage, tips for organizing...
Emerging Global Leaders in Biosimilar Development: Regulatory Guidance and Cost Impact
BIOLOGICS PLAY A KEY ROLE in cancer treatment and are the principal components of many therapeutic regimens.1 However, they require complex manufacturing processes, resulting in high cost and occasional shortages in supply, limiting the accessibility of cancer treatment for many patients, more so ...
Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors
With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...
‘Sidedness’ in Colon Cancer: Using the Data in the Clinic
The evidence from clinical trials has established that “side matters” when it comes to colorectal cancer outcomes. How do clinicians use this information in their practices? Christina Wu, MD, of Emory University, shared her thoughts with attendees at the 2017 Debates and Didactics in Hematology and ...
Genetic Variant May Significantly Lower Risk of Breast Cancer in Women With History of Preeclampsia
Researchers have demonstrated that women with a history of preeclampsia have as much as a 90% decrease in breast cancer risk if they carry a specific common gene variant. Further studies are now underway to determine the mechanism of this protection in an effort to develop new breast cancer...
Integration of Oncology and Palliative Care in a Solid Tumor Inpatient Service
In a retrospective study reported in the Journal of Oncology Practice, Riedel et al found that integration of oncology and palliative care in a solid tumor inpatient service resulted in improvements in quality-of-care metrics during the first year of implementation. Study Details The study...
HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors
The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...
Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer
A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...
ASCO/Cancer Care Ontario Joint Guideline Update: Brachytherapy for Patients With Prostate Cancer
AS REPORTED by Joseph Chin, MD, of London Health Sciences Centre, London, Ontario, and colleagues in the Journal of Clinical Oncology, ASCO and Clinical Care Ontario (CCO) have issued a joint update to the prior CCO guideline on use of brachytherapy in patients with prostate cancer.1,2 The update ...
Pursuing Combination Strategies With Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma
PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the incidence and...
New ASCO Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment
AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1 (NK1)...
Deep Androgen Suppression Plus Abiraterone and Prednisone: Effective Strategy for Hormone-Naive Prostate Cancer
ANTAGONISM OF THE ANDROGEN AXIS remains a cornerstone of systemic therapy for high-risk localized and metastatic prostate cancer, reflecting the central role of androgen-dependent biologic mechanisms in hormone-naive disease. Despite the use of standard androgen-deprivation therapy, men with...
Updates of Key Trials in Metastatic Non–Small Cell Lung Cancer: KEYNOTE-024 and AvaALL
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of Thoracic Medical...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Heath D. Skinner, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous ...
Look for Opportunities to Lower Barriers to Participation of Older Patients in Oncology Clinical Trials
Practicing evidence-based medicine requires evidence, but the evidence for efficacy and safety of new and evolving cancer therapies in older adults is wanting due to their underrepresentation in oncology clinical trials. “It is difficult to practice evidence-based medicine in an older population...
‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, FACP, FASCO, noted in an interview with The ASCO Post. Prompting those changes are...
FDA Accepts sBLA and Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell Lymphoma
On August 16, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL). The sBLA and its acceptance is based on data from the phase III...
Turmeric
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
Unraveling the Complexities of Cellular Immunotherapy and Its Potential to Cure Some Cancers
This past fall, the Fred Hutchinson Cancer Research Center in Seattle opened an all-encompassing 9,222-square foot outpatient cellular immunotherapy clinic, specifically designed to serve patients participating in the center’s novel immunotherapy clinical trials, which mainly focus on chimeric...
ASCO Guideline on Stage IV NSCLC Therapy Updated
An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical Oncology, also provides new...
Lung Cancer Clinical Trial Eligibility Criteria Increase in Number, Complexity
With the advent of molecular targeted therapies and immunotherapy, eligibility criteria have increased in number and complexity for lung cancer clinical trials, according to an analysis published by Garcia et al in the Journal of Thoracic Oncology. Despite calls to streamline cancer clinical trial...
Senate Passes the RACE for Children Act
On August 3, the leadership of Kids v Cancer, an advocacy group promoting pediatric cancer research, issued the following statement: Today, the U.S. Senate passed the FDA Reauthorization Act and with it, the RACE for Children Act. Now, new cancer drugs will be developed not only for...
Practice Engagement Program Connects Practices to Resources to Adapt to Health-Care Changes
ASCO launched its Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. The Practice Engagement...
ASCO President Bruce E. Johnson Seeks to Bring Personalized Medicine, Real-Time Data to Every Oncology Practice
Dedicating one’s career and livelihood to the pursuit of treating and possibly curing cancer is, for many, a decision that stems from deeply personal and, often, tragic experience. For 2017–2018 ASCO President Bruce E. Johnson, MD, FASCO, the event that greatly influenced his decision was the...
Blinatumomab in Advanced Acute Lymphoblastic Leukemia: A Brighter Therapeutic Outlook
NEW DRUGS that will improve the outcome of adult patients who develop a deadly disease such as acute leukemia are badly needed; combinations of cytotoxic chemotherapeutic drugs may have reached an upper limit of utility. Agents that eradicate leukemia by alternative mechanisms would be of...
NYU Perlmutter Creates New Pancreatic Cancer Center
PERLMUTTER CANCER CENTER at NYU Langone has announced the creation of a multidisciplinary center of excellence to develop innovative approaches to diagnose, treat, and prevent pancreatic cancer. The new Pancreatic Cancer Center brings together laboratory researchers, surgeons, oncologists,...
Alectinib: A New Standard for First-Line Therapy of ALK-Rearranged NSCLC?
ANAPLASTIC LYMPHOMA KINASE (ALK) was first identified in anaplastic large cell lymphoma. The ALK gene itself is not oncogenic, but it can become oncogenic by at least three mechanisms: by forming a fusion gene with a number of other partner genes, by copy number gain, or by mutations in the gene....
